(Q39965627)

16 September 2017

Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy (English)

1 reference

inflammatory bowel diseases

16 September 2017

0 references

TNF

0 references

TNF inhibitor

0 references

author

Laurent Peyrin-Biroulet

12

object named as

Laurent Peyrin-Biroulet

1 reference

16 September 2017

Maria Nachury

5

0 references

Philippe Seksik

object named as

Philippe Seksik

2

0 references

Laurent Beaugerie

3

object named as

Laurent Beaugerie

1 reference

16 September 2017

Florian Poullenot

1

1 reference

16 September 2017

Aurélien Amiot

4

1 reference

16 September 2017

Vered Abitbol

6

1 reference

16 September 2017

Carmen Stefanescu

7

1 reference

16 September 2017

Catherine Reenaers

8

1 reference

16 September 2017

Mathurin Fumery

9

1 reference

16 September 2017

Anne-Laure Pelletier

10

1 reference

16 September 2017

Stephane Nancey

11

1 reference

16 September 2017

Arnaud Bourreille

13

1 reference

16 September 2017

Xavier Hébuterne

14

1 reference

16 September 2017

Hedia Brixi

15

1 reference

16 September 2017

Guillaume Savoye

16

1 reference

16 September 2017

Nelson Lourenço

17

1 reference

16 September 2017

Romain Altwegg

18

1 reference

16 September 2017

Anthony Buisson

19

1 reference

16 September 2017

Christine Cazelles-Boudier

20

1 reference

16 September 2017

Antoine Racine

21

1 reference

16 September 2017

Julien Vergniol

22

1 reference

16 September 2017

David Laharie

23

1 reference

16 September 2017

le GETAID

24

1 reference

16 September 2017

24 February 2016

1 reference

Inflammatory Bowel Diseases

16 September 2017

1 reference

16 September 2017

22

1 reference

16 September 2017

6

1 reference

16 September 2017

1362-1369

1 reference

Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease

16 September 2017

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000741

Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000741

Decreasing colectomy rates for ulcerative colitis: a population-based time trend study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000741

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000741

Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000741

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000741

European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000741

The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000741

Guidelines for the management of basal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000741

Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000741

Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000741

Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000741

The management of immunosuppression in patients with inflammatory bowel disease and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000741

A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9).

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000741

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000741

Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000741

10.1097/MIB.0000000000000741

21 January 2018

Identifiers

DOI

1 reference

16 September 2017

1 reference